平安好醫生(01833.HK)與阿斯利康達成戰略合作 探討打造慢性疾病服務中心
平安好醫生(01833.HK)與阿斯利康於進博會上簽署戰略合作協定。雙方將在藥品零售生態創新、慢病管理等方面展開深度合作,探索對用戶有價值、對行業有助力的醫療健康服務創新模式。
截至今年9月底,平安好醫生線下合作藥店數目18.9萬家,合作醫院超過4,000家,合作體檢機構約1,700家,合作健康機構超過1,800家。通過平安好醫生藥診卡和合作藥房網路,可以使阿斯利康更全面地覆蓋零售渠道,併發揮優勢,賦能更多線下藥房,完善醫療O2O,共同保障用戶無縫的服務體驗。用戶不僅享有線上問診、購藥等服務,還能獲得高性價比的用藥體驗。
阿斯利康的藥品研發生產銷售經驗,也將爲平安好醫生提供場景引導和支援。通過爲線上醫生提供系統性藥學知識培訓,提升線上零售藥店用戶活躍度,爲後續共同探索零售藥店生態提供場景基礎。
另外,根據戰略合作協定,雙方將發揮各自優勢,攜手共同探討打造慢性疾病服務中心,爲有慢性疾病篩查及管理需求的使用者構建線上服務場景。基於多種慢性疾病服務,共同探索多場景、多渠道的慢性疾病服務延展可能性,爲類型繁多、涉及科室廣泛的慢性疾病診療創造便利。
雙方還將在品牌旗艦店、疾病科普等方面進行合作,進一步爲醫藥產業鏈提供互聯網+醫療健康的智慧解決方案,爲使用者提供更有溫度的服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.